Granted Patent
B2
US 12,497,457 · App. 17/819,218 · Granted Dec 16, 2025
Methods and compositions for inhibiting CD32B expressing cells in IGG4-related diseases
Inventors:
Seung Yup Chu (Cypress, CA); John R. Desjarlais (Pasadena, CA); Sher Bahadur Karki (Pomona, CA); Gregory Alan Lazar (Arcadia, CA); Gregory L. Moore (Monrovia, CA); Igor Vostiar (Monrovia, CA)
Assignee:
Xencor, Inc.
C07K16/283C07K16/00C07K16/2803C07K16/2851C07K16/2878A61K2039/505C07K2317/24C07K2317/31C07K2317/52C07K2317/524C07K2317/53C07K2317/71C07K2317/72C07K2317/73C07K2317/732C07K2317/734C07K2317/76C07K2317/77C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
Claims (14)
1 . An anti-CD19 immunoglobulin comprising:
a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of SEQ ID NO: 2; and
a light chain CDR1, a light chain CDR2, and a light chain CDR3 of SEQ ID NO: 1,
and wherein the antibody comprises amino acid substitutions S267E and L328F, wherein the numbering is according to the EU index as in Kabat.
2 . The antibody according to claim 1 , wherein said heavy chain comprises SEQ ID NO: 9.
3 . The antibody according to claim 1 , wherein said light chain comprises SEQ ID NO: 7.
4 . A pharmaceutical composition comprising an antibody according claim 1 and a pharmaceutically acceptable carrier.
5 . The pharmaceutical composition of claim 4 , wherein the antibody comprises a heavy chain comprising SEQ ID NO: 9 and a light chain comprising SEQ ID NO: 7.
6 . A method of inhibiting at least one B-cell comprising administering an anti-CD19 immunoglobulin comprising:
a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of SEQ ID NO: 2; and
a light chain CDR1, a light chain CDR2, and a light chain CDR3 of SEQ ID NO: 1,
and wherein the antibody comprises amino acid substitutions S267E and L328F, wherein the numbering is according to the EU index as in Kabat.
7 . The method of claim 6 , wherein said heavy chain comprises SEQ ID NO: 9.
8 . The method of claim 6 , wherein said light chain comprises SEQ ID NO: 7.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 21, 2023
From: CHU, SEUNG YUP; DESJARLAIS, JOHN R.; KARKI, SHER BAHADUR; LAZAR, GREGORY ALAN; MOORE, GREGORY L.; VOSTIAR, IGOR
To: XENCOR, INC.
Reel/Frame 064013/0143 →
Continuity (14)
Provisional Application
60940776
· May 30, 2007
Provisional Application
60953174
· Jul 31, 2007
Provisional Application
60970413
· Sep 6, 2007
Provisional Application
60976279
· Sep 28, 2007
Provisional Application
60990509
· Nov 27, 2007
Provisional Application
61012035
· Dec 6, 2007
Provisional Application
61013775
· Dec 14, 2007
Provisional Application
61019395
· Jan 7, 2008
Provisional Application
61032059
· Feb 27, 2008
Provisional Application
61043585
· Apr 9, 2008
Provisional Application
61046397
· Apr 18, 2008
References Cited (304)
US 3773919A
· Boswell et al.
· 1973
[cited by applicant]
US 4485045A
· Regen et al.
· 1984
[cited by applicant]
US 4544545A
· Ryan et al.
· 1985
[cited by applicant]
US 4975278A
· Senter et al.
· 1990
[cited by applicant]
US 5013556A
· Woodle et al.
· 1991
[cited by applicant]
US 5208020A
· Chari et al.
· 1993
[cited by applicant]
US 5264586A
· Nicolaou et al.
· 1993
[cited by applicant]
US 5587459A
· Uckun
· 1996
[cited by applicant]
US 5677165A
· De Boer et al.
· 1997
[cited by applicant]
US 5686072A
· Uhr et al.
· 1997
[cited by applicant]
US 5693762A
· Queen et al.
· 1997
[cited by applicant]
US 5712374A
· Kuntsmann et al.
· 1998
[cited by applicant]
US 5714586A
· Kuntsmann et al.
· 1998
[cited by applicant]
US 5773001A
· Hamann et al.
· 1998
[cited by applicant]
US 5804396A
· Plowman et al.
· 1998
[cited by applicant]
US 6403312B1
· Dahiyat et al.
· 2002
[cited by applicant]
US 6602684B1
· Umana et al.
· 2003
[cited by applicant]
US 6737056B1
· Presta et al.
· 2004
[cited by applicant]
US 6797492B2
· Daugherty et al.
· 2004
[cited by applicant]
US 6821505B2
· Ward et al.
· 2004
[cited by applicant]
US 7052873B2
· Tsuchiya et al.
· 2006
[cited by applicant]
US 7083784B2
· Dall'Acqua et al.
· 2006
[cited by applicant]
US 7117096B2
· Luo et al.
· 2006
[cited by applicant]
US 7129261B2
· Ng et al.
· 2006
[cited by applicant]
US 7217797B2
· Hinton et al.
· 2007
[cited by applicant]
US 7217798B2
· Hinton et al.
· 2007
[cited by applicant]
US 7288251B2
· Bedian et al.
· 2007
[cited by applicant]
US 7315786B2
· Dahiyat et al.
· 2008
[cited by applicant]
US 7317091B2
· Lazar et al.
· 2008
[cited by applicant]
US 7335742B2
· Presta et al.
· 2008
[cited by applicant]
US 7338660B2
· Bedian et al.
· 2008
[cited by applicant]
US 7361740B2
· Hinton et al.
· 2008
[cited by applicant]
US 7365168B2
· Hinton et al.
· 2008
[cited by applicant]
US 7371826B2
· Presta et al.
· 2008
[cited by applicant]
US 7425619B2
· Koenig et al.
· 2008
[cited by applicant]
US 7425620B2
· Koenig et al.
· 2008
[cited by applicant]
US 7445780B2
· Chu et al.
· 2008
[cited by applicant]
US 7563442B2
· Bedian et al.
· 2009
[cited by applicant]
US 7618633B2
· Bedian et al.
· 2009
[cited by applicant]
US 7626012B2
· Bedian et al.
· 2009
[cited by applicant]
US 7662925B2
· Lazar et al.
· 2010
[cited by applicant]
US 8063187B2
· Chu
· 2011
[cited by examiner]
US 8323653B2
· Damschroder et al.
· 2012
[cited by applicant]
US 8362210B2
· Lazar et al.
· 2013
[cited by applicant]
US 8388971B2
· Bedian et al.
· 2013
[cited by applicant]
US 9079960B2
· Chu et al.
· 2015
[cited by applicant]
US 9260523B2
· Chu et al.
· 2016
[cited by applicant]
US 9394366B2
· Chu et al.
· 2016
[cited by applicant]
US 9738722B2
· Moore et al.
· 2017
[cited by applicant]
US 20020048772A1
· Dahiyat et al.
· 2002
[cited by applicant]
US 20020119492A1
· Chirino et al.
· 2002
[cited by applicant]
US 20030003097A1
· Reff et al.
· 2003
[cited by applicant]
US 20030130827A1
· Desjarlais et al.
· 2003
[cited by applicant]
US 20030157108A1
· Presta et al.
· 2003
[cited by applicant]
US 20040110226A1
· Lazar et al.
· 2004
[cited by applicant]
US 20040136908A1
· Olson
· 2004
[cited by examiner]
US 20040230380A1
· Chirino et al.
· 2004
[cited by applicant]
US 20050118174A1
· Presta et al.
· 2005
[cited by applicant]
US 20050249723A1
· Lazar et al.
· 2005
[cited by applicant]
US 20060067930A1
· Adams et al.
· 2006
[cited by applicant]
US 20060134105A1
· Lazar et al.
· 2006
[cited by applicant]
US 20060148009A1
· Barbosa et al.
· 2006
[cited by applicant]
US 20060177439A1
· Koenig et al.
· 2006
[cited by applicant]
US 20060233791A1
· Tedder et al.
· 2006
[cited by applicant]
US 20070135620A1
· Chamberlain et al.
· 2007
[cited by applicant]
US 20080260731A1
· Bernett et al.
· 2008
[cited by applicant]
US 20120082664A1
· Bernett et al.
· 2012
[cited by applicant]
US 20120263732A1
· Gladue et al.
· 2012
[cited by applicant]
US 20130024956A1
· Bedian et al.
· 2013
[cited by applicant]
US 20140010812A1
· Ravetch et al.
· 2014
[cited by applicant]
WO WO1981001145A1
· 1981
[cited by applicant]
WO WO1988007378A1
· 1988
[cited by applicant]
WO WO199211018A1
· 1992
[cited by applicant]
WO WO1993021232A1
· 1993
[cited by applicant]
WO WO1996030347A1
· 1996
[cited by applicant]
WO WO1996033978A1
· 1996
[cited by applicant]
WO WO1996033980A1
· 1996
[cited by applicant]
WO WO1997034631A1
· 1997
[cited by applicant]
WO WO1997038731A1
· 1997
[cited by applicant]
WO WO1997038983A1
· 1997
[cited by applicant]
WO WO1998043960A1
· 1998
[cited by applicant]
WO WO1999006378A1
· 1999
[cited by applicant]
WO WO1999006396A1
· 1999
[cited by applicant]
WO WO1999009016A1
· 1999
[cited by applicant]
WO WO2000061739A1
· 2000
[cited by applicant]
WO WO2001029246A1
· 2001
[cited by applicant]
WO WO2001059066A2
· 2001
[cited by applicant]
WO WO2002030954A1
· 2002
[cited by applicant]
WO WO2002031140A1
· 2002
[cited by applicant]
WO WO2002060919A2
· 2002
[cited by applicant]
WO WO2003014325A2
· 2003
[cited by applicant]
WO WO2003029296
· 2003
[cited by applicant]
WO WO2003074679
· 2003
[cited by applicant]
WO WO2004004798A2
· 2004
[cited by applicant]
WO WO2004035752A2
· 2004
[cited by applicant]
WO WO2004091658A1
· 2004
[cited by applicant]
WO WO2004092219A2
· 2004
[cited by applicant]
WO WO2005037867A1
· 2005
[cited by applicant]
WO WO2005047327A2
· 2005
[cited by applicant]
WO WO2006019447A2
· 2006
[cited by applicant]
WO WO2006031370A2
· 2006
[cited by applicant]
WO WO2006047350A2
· 2006
[cited by applicant]
WO WO2006053301A2
· 2006
[cited by applicant]
WO WO2006105338A2
· 2006
[cited by applicant]
WO WO2006133450A2
· 2006
[cited by applicant]
Amendment and Response to Office Action, U.S. Appl. No. 13/294,103, filed Nov. 22, 2013 (16 pages).
[cited by applicant]
Amendment and Response to Office Action, U.S. Appl. No. 13/294,103, filed Jan. 29, 2015 (20 pages).
[cited by applicant]
Amendment and Response to Office Action, U.S. Appl. No. 13/301,627, filed Jan. 5, 2015 (23 pages).
[cited by applicant]
Amendment and Response to Final Office Action, U.S. Appl. No. 13/594,619, filed Dec. 2, 2013 (9 pages).
[cited by applicant]
Amendment and Response to Non-Final Office Action, U.S. Appl. No. 13/594,619, filed May 7, 2013 (9 pages).
[cited by applicant]
Amendment and Response to Non-Final Office Action, U.S. Appl. No. 13/301,627, filed Aug. 30, 2012 (21 pages).
[cited by applicant]
Amendment and Response to Non-Final Office Action, U.S. Appl. No. 12/156,183, filed Apr. 4, 2011 (9 pages).
[cited by applicant]
Amendment and Response to Non-Final Office Action, U.S. Appl. No. 12/156,184, filed Mar. 3, 2011 (8 pages).
[cited by applicant]
Amendment and Response to Non-Final Office Action, U.S. Appl. No. 13/294,103, filed Aug. 30, 2012 (18 pages).
[cited by applicant]
Amendment and Response to Final Office Action, U.S. Appl. No. 13/301,627, filed Sep. 9, 2013 (19 pages).
[cited by applicant]
Amendment and Response to Restriction Requirement, U.S. Appl. No. 12/156,183, filed Sep. 2, 2010 (8 pages).
[cited by applicant]
Amendment and Response to Restriction Requirement, U.S. Appl. No. 13/294,103, filed Aug. 10, 2012 (10 pages).
[cited by applicant]
Amendment and Response to Restriction Requirement, U.S. Appl. No. 13/594,619, filed Nov. 19, 2012 (9 pages).
[cited by applicant]
Amendment and Response to Restriction Requirement, U.S. Appl. No. 13/301,627, filed Jul. 30, 2012 (7 pages).
[cited by applicant]
Response to Office Action, U.S. Appl. No. 13/594,619, filed Sep. 2, 2014 (10 pages).
[cited by applicant]
Amigorena, et al., “Cytoplasmic domain heterogeneity and functions of IgG receptors in B lymphocytes” Science, (1992), 1808-1812, vol. 256, No. 5065.
[cited by applicant]
Ashkenazi, et al., “Immunoadhesins as research toolls and therapeutic agents” Curr. Opinin Immunol, 1997, 195-200, vol. 9.
[cited by applicant]
Atwell, et al., “Stable Heterodimers from Remodeling the Domain Interface of a Homodimer using a Phage Display Library” J. Mal. Biol, 1997, 26-35, vol. 270.
[cited by applicant]
Barbin et al., “Influence Of Variable N-Glycosylation On The Cytolytic Potential OfChimeric CD19 Antibodies”, J. Immun., 29:2, Mar./Apr. 2006, pp. 122-133.
[cited by applicant]
Beigier-Bompadre, et al “The Formyl Peptide N-Fornyl-methionly-leucyl-phenylalanine Downregulates the Expression of FcγRs in Interferon-γ-Activated Monocytes/Macrophages In Vitro and In Vivo” Scand. J. Immunol., 2003, p…
[cited by applicant]
Bjork et al., “The CD40 agonistic monoclonal antibody APX005M has potent immune stimulatory capabilities”, Journal for Immunotherapy of Cancer, vol. 3, Suppl. 2, 2015, pp. 198.
[cited by applicant]
Binstadt, et al., “IgG Fe receptor polymorphisms in human disease: Implications for intravenous immunoglobulin therapy”, J. Allergy and Clinical Immuno., (2003), 697-703, vol. 111, No. 4.
[cited by applicant]
Bitonti, et al.“Pulmonary delivery of an erythropoietin Fe fusion protein in non-human primates through an immunoglobulin transport pathway” Proc. Natl. Acad. Sci., 2004, 9763- 9768, vol. 101.
[cited by applicant]
Blank, et al., “Decreased transcription of the human FCGR2B gene mediated by the—343G/C promoter polymorphsm and association with systemic lupus erythematosus” Human Genetics, 2005, 220-227, vol. 117, No. 2.
[cited by applicant]
Bruggemann et al., “Production of human antibody repertoires in transgenic mice” Current Opinion in Biotech., 1997, 455-458, vol. 8.
[cited by applicant]
Campbell et al., “A dominant mutation to ricin resistance in Chinese hamsterovary cells induces UDP-GlcNAc:Glycopeptide beta-4-N-acetylglucosaminyltransferase III activity” J. Biol. Chem., 1984, 13370-13378, vol. 259, N…
[cited by applicant]
Caron, et al “Engineered Humanized Dimeric Forms of IgG Are More Effective Antibodies” J. Exp. Med., 1992, 1191-1195, vol. 176.
[cited by applicant]
Carter, et al., “Bispecific human IgG by design” J. Immunol. Methods, 2001, 7-15, vol. 248.
[cited by applicant]
Carter, et al., “Potent antibody therapeutics by design” Nature Reviews, 2006, 343-357, vol. 6.
[cited by applicant]
Cartron, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fe receptor FcyRllla gene Blood, 2002, vol. 99, No. 3.
[cited by applicant]
Chamow, et al, “Immunoadhesins : principles and applications” Trends in Biotechnology, 1996, 52-60, vol. 14, No. 2.
[cited by applicant]
Chan, et al “Regulation of the immune response. VI. Inaility of F(ab′) 2 anitbody to terminate established immune responses and its ability to interfere with IgG antibody-mediated immunosuppression” Immunology, 1973, 28…
[cited by applicant]
Chari, et al “Immunoconjugates Containing Novel Maytansinoids: Promising AnticancerDrugs” Cancer Research, 1992, 127-131, vol. 52.
[cited by applicant]
Chen, et al., “Association of a transmembrane polymorphism of Fey receptor llb (FCGR2B)with systemic lupus erythematosus in Taiwanese patients” Arthritis and rheumatism, 2006, 3908-3917, vol. 54, No. 12.
[cited by applicant]
Chin, et al., “An Expanded Eukaryotic Genetic Code” Science, 2003, 964-967, vol. 301.
[cited by applicant]
Chu, et al., “Coengagement of BCR coreceptor CD19 and inhibitory Fe receptor gammaRllb suppresses B cell function: a potential therapeutic strategy for autoimmunedisease” Internet Citation, www.Xencor.com/downloads/bios…
[cited by applicant]
Chu, et al., “Inhibition of B cell receptor-mediated activation of primary human B cells by conegagement of CD19 and FcgammaRIIb with Fe-engineered antibodies” Molecular Immunology, 2008, 3926-3933, vol. 45, No. 15.
[cited by applicant]
Clark, “IGG Effector Mechanisms” Chemical Immunology, 1997, 88-110, vol. 65.
[cited by applicant]
Colman et al., “Effects of Amino Acid Sequence Changes On Antibody-antigen Interactions”, Research in Immunology, vol. 145, No. 1, 1994, pp. 33-36.
[cited by applicant]
Cox, et al “Glycan optimization of a human monoclonal antibody in the aquatic plantLemna minor” Nature Biotechnology, 2006, 1591-1597, vol. 24, No. 2.
[cited by applicant]
Cropp, et al “An expanding genetic code” Trends in Genetics, 2004, 625-630, vol. 20,No. 12.
[cited by applicant]
Dall'Acqua, et al.“Increasing the affinity of a human IgG1 for the neonatal Fe receptor: Biological consequences” J. Immunol, 2002, 5171-5180, vol. 169.
[cited by applicant]
Dall'Ozzo, et al.“Rituximab-Dependent Cytotoxicity by Natural Killer Cells: Influence of FCGR3A Polymorphism on the Concentration-Effect Relationship” Cancer Research, 2004, 4664-4669, vol. 64.
[cited by applicant]
Davies, et al.“Expression of Gntlll in a recombinant ati-cd20 cha production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity fo FcγRIII” Biotechnology and…
[cited by applicant]
Davies, et al“Fe receptor homologs: newest members of a remarkable diverse Fereceptor gene family” Immunological Reviews, 2002, 123-136, vol. 190.
[cited by applicant]
De Goer De Herve et al., “Differential Effect of Agonistic Anti-CD40 on Human Mature and Immature Dendritic Cells: The Janus Face of Anti-CD-40”, Blood, vol. 106, 2005, pp. 2806-2814.
[cited by applicant]
Defranco, et al, “The Complexity of Signaling Pathways Activated by the BCR” Curr. Opin, in Immunol., 1997, 296-308, vol. 9.
[cited by applicant]
Desai, et al., “Fcy Receptor IIB on Dendritic Cells Enforces Peripheral Tolerance by Inhibiting Effecetor T Cell Responses” J. Immuno., 2007, 6217-6226, vol. 178.
[cited by applicant]
De Pascalis, et al., “Grafting of ‘Abbreviated’ Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody” …
[cited by applicant]
Dhodapkar et al., “Selective Blockade of Inhibitory Fcγ Receptor Enables Human Dendritic Cell Maturation with IL-12p70 Production and Immunity to Antibody-Coated Tumor Cells”, PNAS, vol. 102, No. 8, 2005, pp. 2910-2915.
[cited by applicant]
Dickinson, et al, “Bidirectional FcRn-dependent IgG transport in a polarized humanintestinal epithelial cell line” J. Clin. Invest, 1999, 903-911, vol. 104.
[cited by applicant]
Doody, et al “Activation of B lymphocytes: integrating signals from CD19, CD22 and FcγRIIb1” Curr. Opin. Immunol., 1996, 378-382, vol. 8.
[cited by applicant]
Doronina, et al.“Development of potent monoclonal antibody auristatin conjugates forcancer therapy” Nature Biotech, 2003, 778-784, vol. 21, No. 7.
[cited by applicant]
Edelman, et al “The Covalent Structure of an Entire yG Immunoglobulin Molecule”Biochemistry, 1969, 78-85, vol. 63.
[cited by applicant]
Eppstein, et al “Biological activity of liposome-encapsulated murine interferon γ is mediated by a cell membrane receptor” Proc. Natl. Acad. Sci., 1985, 3688-3692, vol. 82.
[cited by applicant]
Examiner Interview Summary, U.S. Appl. No. 12/156,183, filed Aug. 24, 2010 (3 pages).
[cited by applicant]
Examiner Interview Summary, U.S. Appl. No. 12/156,183, filed Jan. 20, 2011 (3 pages).
[cited by applicant]
Final Office Action, U.S. Appl. No. 13/301,627, filed Aug. 4, 2014 (25 pages).
[cited by applicant]
Final Office Action, U.S. Appl. No. 13/594,619, filed Jul. 1, 2013 (9 pages).
[cited by applicant]
Final Office Action, U.S. Appl. No. 13/301,627, filed Apr. 9, 2013 (20 pages).
[cited by applicant]
Final Office Action, U.S. Appl. No. 12/156,184, filed Apr. 12, 2011 (12 pages).
[cited by applicant]
Final Office Action, U.S. Appl. No. 13/294,103, filed Feb. 11, 2013 (23 pages).
[cited by applicant]
Floto, et al., “Loss of function of a lupus-associated FcγRIIb polymorphism throughexclusion from lipid rafts” Nature Medicine, 2005, 1056-1058, vol. 11, No. 10.
[cited by applicant]
Francisco, et al “cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate withpotent and selective antitumor activity” Blood, 2003, 1458-1465, vol. 102, No. 4.
[cited by applicant]
Fukuyama, et al. “The inhibitory Fcγ receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells” Nature Immunology, 2005, 99-106, vol. 6, No. 1.
[cited by applicant]
Gabizon, et al “Pharmacokinetics and Tissue Distribution of Doxorubicin Encapsulated in Stable Liposomes with Long Circulation Time” J. Natl. Cancer Inst., 1989, 1484-1488, vol. 18.
[cited by applicant]
Ghetie, et al “Multiple roles for the Major Histocompatibility Complex Class I-RelatedReceptor FcRn” Annual Rev. Immunol., 2000, 739-766, vol. 18.
[cited by applicant]
Gorman, et al “Humanisation of monoclonal antibodies for therapy” Semin Immunol., 1990, 457-466, vol. 2, No. 6.
[cited by applicant]
Griffiths, et al “Strategies for selection of antibodies by phage display” Current Opinionin Biotech, 1998, 102-108, vol. 9.
[cited by applicant]
Hager et al., “Affinity and Epitope Profiling of Mouse Anti-CD40 Monoclonal Antibodies”, Scandinavian Journal of Immunology, vol. 57, 2003, pp. 517-524.
[cited by applicant]
Hayhurst, et al“High-throughput antibody isolation” Current Opinion in Chem Biol.,2001, 683-689, vol. 5.
[cited by applicant]
Heyman, et al “Feedback regulation by IgG antibodies” Immunol. Letters, 2003, 157-161, vol. 88, No. 2.
[cited by applicant]
Hinman, et al “Preparation and Characterization of Monoclonal Antibody Conjugates of theCalicheamicins: A Novel and Potent Family of Antitumor Antibiotics” Cancer Research, 1993, 3336-3341, vol. 53.
[cited by applicant]
Hinton, et al “Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates” J. Biol. Chem., 2004, 6213-6216, vol. 279, No. 8.
[cited by applicant]
Hinton, et al “An engineered human lgG1 antibody with longer serum half-life” J.Immunol, 2006, 346-356, vol. 176, No. 1.
[cited by applicant]
Hogarth, et al “Fc receptors are major mediators of antibody based inflammation inautoimmunity” Current Opinion in Immunol., 2002, 798-802, vol. 14.
[cited by applicant]
Holliger, et al “Engineered antibody fragments and the rise of single domains: Antibodyengineering and manufacture” Nature Biotech., 2005, 1126-1136, vol. 23, No. 9.
[cited by applicant]
Horton et al., “Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia”, American Association for Cancer Research, The Journal of Cancer Research, vol. 68, N…
[cited by applicant]
Hubbard, et al “Synthesis and Processing of Asparagine-Linked Oligosaccharides” Annual Rev. Biochem, 1981, 555-583, vol. 50.
[cited by applicant]
Hwang, et al, “Hepatic uptake and degradation of unilamellar sphingomyelin/ cholesterolliposomes: A kinetic study” Proc. Natl. Acad. Sci, 1980, 4030-4034, vol. 77, No. 7.
[cited by applicant]
Issue Notification, U.S. Appl. No. 12/156,183, filed Nov. 2, 2011 (1 page).
[cited by applicant]
Jefferis, et al “IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation” Immuno. Rev, 1998, 59-76, vol. 163.
[cited by applicant]
Jefferis, et al “Interaction sites on human IgG-Fc for FcγR: current models” Immunol. Letters, 2002, 57-65, vol. 82, No. 1.
[cited by applicant]
Jones, et al “Replacing the complementarity-determining regions in a human antibody withthose from a mouse” Nature, 1986, 522-525, vol. 321.
[cited by applicant]
Kan, et al “Thioether-Bonded Constructs of Fab'γ and Fey Modules Utilizing DifferentialReduction of Interchain Disulfide Bonds” J. Immunol., 2001, 1320-1326, vol. 166.
[cited by applicant]
Kaneko, et al “Anti-inflammatory activity of immunoglobulin G resulting from Fe sialylation” Science, 2006, 670-673, vol. 313, No. 5787.
[cited by applicant]
Kiener, et al “Co-ligiation of the antigen and Fe receptors gives rise to the selectivemodulation of intracellular signaling in b cells: regulation of the association of phosphatidylinositol 3-kinase and inositol 5-phos…
[cited by applicant]
Kim, et al “Analysis of FcγRIII and IgG Fc Polymorphism Reveals Functional and Evolutionary Implications of Protein-Protein Interaction” J. Mal. Evol., 2001, 1-9, vol. 53.
[cited by applicant]
Lapusan et al., “Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia”, Invest New Drugs, vol. 30, 2012, pp. 1121-1131, DOI: 10.1007…
[cited by applicant]
Lazar Declaration, Dec. 27, 2012, pp. 1-4.
[cited by applicant]
Lefranc, et al “Gm, Am and Km immunoglobulin allotypes of two populations in Tunisia”Human Genetics, 1979, 199-211, vol. 50, No. 2.
[cited by applicant]
Li, et al “Optimization of humanized IgCs in glycoengineered Pichia pastoris” NatureBiotech, 2006, 210-215, vol. 24, No. 2.
[cited by applicant]
Li, et al “CD72 down-modulates BCR-induced signal transduction and diminishes survivalin primary mature B lymphocytes” J. Immunol.,2006, 5321-5328, vol. 176, No. 9.
[cited by applicant]
Li, et al “A novel polymorphism in the Fcγ receptor IIb (CD32B) transmembrane region altersreceptor signaling” Arthritis and Rheumatism, 2003, 3242-3252, vol. 48, No. 11.
[cited by applicant]
Li et al., “Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies”, Science, vol. 333, 2011, pp. 1030-1034.
[cited by applicant]
Lifely, et al “Glycosylation and biological activity of campath-1H expressed in different cell lines and grown under different culture conditions” Glycobiology, 1995, 813-822 vol. 5,No. 8.
[cited by applicant]
Lode, et al., “Targeted therapy with a novel enediyene antibiotic calichemamicin 8
[cited by applicant]
Lowman, et al “Selecting high-affinity binding proteins by monovalent phage display” Biochemistry, 1991, 10832-10838, vol. 30, No. 45.
[cited by applicant]
Mackay, et al “Selective dysregulation of the FcγIIB receptor on memory B cells in Sle” J. Exp.Med., 2006, 2157-2164, vol. 203, No. 9.
[cited by applicant]
Massey, “Catalytic antibodies catching on” Nature, 1987, 457-458, vol. 320.
[cited by applicant]
Matsuura et al., “Is atherosclerosis an autoimmune disease?”, BMC Medicine, vol. 12, No. 47, 2014, pp. 1-5.
[cited by applicant]
Maynard, et al, “Antibody Engineering” Annu. Rev. Biomed. Engin, 2000, 339-376, vol. 2.
[cited by applicant]
McGaha, et al “Restoration of tolerance in lupus by targeted inhibitory receptorexpression” Science, 2005, 590-593.
[cited by applicant]
Mease et al., “B Cell-Targeted Therapy in Autoimmune Disease: Rationale, Mechanisms, and Clinical Application”, The Journal of Rheumatology, vol. 35, No. 7, 2008, pp. 1245-1255.
[cited by applicant]
Mechetina, et al “Identification of CD16-2, a novel mouse receptor homologus toCD16/FcγRIII” Immunogenetics, 2002, 463-468, vol. 54.
[cited by applicant]
Meeker, et al.,“A unique human B lymphocyte antigen defined by a monoclonal antibody”Hybridoma, 1984, 305-320, vol. 3, No. 4.
[cited by applicant]
Mihaylova, et al., “Selective silencing of disease-associated B-lymphocytes by chimeric molecules targeting their Fe gamma IIb receptor” International Immunology, 2008, 165-175, vol. 20, No. 2.
[cited by applicant]
Mimura, et al“Role of Oligosaccharide Residues of IgG1-Fc in FcγRIIB Binding” J. Biol. Chem., 2001, 45539-45547, vol. 276, No. 49.
[cited by applicant]
Morea, et al “Antibody structure, prediction and redesign” Biophysical Chem., 1997, 9-16, vol. 68.
[cited by applicant]
Morea, et al “Antibody Modeling: Implications for Engineering and Design” Methods,2000, 267-279, vol. 20.
[cited by applicant]
Muta, et al “A 13-amino-acid motif in the cytoplasmic domain of FcγRIIB modulates B-cell receptor signaling” Nature, 1994, 70-73, vol. 368, No. 6466.
[cited by applicant]
Nakamura, et al“Fcγ Receptor 11B-deficient Mice Develop Goodpastures's Syndrome upon Immunization with Type IV Collagen: A Novel Murine Model for Autoimmune Glomerular Basement Membrane Disease” J. Exp. Med., 2000, 899-…
[cited by applicant]
Nechansky, et al “Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glycol-engineering of therapeutic antibodies” Mole. Immuno., 2007, 1826-1828, vol. 44, No. 7.
[cited by applicant]
Nielsen, et al., “Regulation of B-Cell Activation by Complement Receptors and FeReceptors” Transfus Med Hemother, 2005, 339-347, vol. 32.
[cited by applicant]
Nimmerjahn, et al., “Fe gamma receptors: Old friends and new family members” Immunity, 2006, 19-28, vol. 24, No. 1.
[cited by applicant]
Niwa et al., Enhancement Of The Antibody-Dependent Cellular Cytotoxicity Of Low-Fucose IgG1 Is Independent Of FcγRIIIa Functional Polymorphism, Clinical Cancer Rsch., vol. 10, Sep. 15, 2004, pp. 6248-6255.
[cited by applicant]
Non-Final Office Action, U.S. Appl. No. 12/156,183, filed Oct. 4, 2010 (15 pages).
[cited by applicant]
Non-Final Office Action, U.S. Appl. No. 13/294,103, filed Aug. 29, 2014 (20 pages).
[cited by applicant]
Non-Final Office Action, U.S. Appl. No. 13/301,627, filed Jan. 20, 2015 (20 pages).
[cited by applicant]
Non-Final Office Action, U.S. Appl. No. 13/594,619, filed Sep. 3, 2014 (10 pages).
[cited by applicant]
Non-Final Office Action, U.S. Appl. No. 13/594,619, filed Feb. 7, 2013 (22 pages).
[cited by applicant]
Non-Final Office Action, U.S. Appl. No. 12/156,184, filed Sep. 3, 2010 (16 pages).
[cited by applicant]
Non-Final Office Action, U.S. Appl. No. 13/294,103, filed Aug. 30, 2012 (18 pages).
[cited by applicant]
Non-Final Office Action, U.S. Appl. No. 13/301,627, filed Aug. 30, 2012 (16 pages).
[cited by applicant]
Notice of Abandonment, U.S. Appl. No. 12/156,184, filed Oct. 28, 2011 (2 pages).
[cited by applicant]
Notice of Allowance and Examiner Interview Summary, U.S. Appl. No. 12/156,183, filed Jun. 28, 2011 (8 pages).
[cited by applicant]
Olferiev, et al “The role of activating protein 1 in the transcriptional regulation of thehuman FCGR2B promoter mediated by the -343 G_C polymorphism associated with systemic lupus eruthematosus” J. Bio. Chem., 2007, 17…
[cited by applicant]
Ono, et al“Role of the inositol phospatase SHIP in negative regulation of the immune system by the receptor FcγRIIB” Nature, 1996, 263-266, vol. 383, No. 6597.
[cited by applicant]
Ozaki et al., “Humanized Anti-HM1.24 Antibody Mediates Myeloma Cell Cytotoxicity that is Enhanced by Cytokine Stimulation of Effector Cells”, Blood, vol. 93, No. 11, 1999, pp. 3922-3930.
[cited by applicant]
Penichet, et al “Antibody-cytokine fusion proteins for the therapy of cancer” J. Immunol. Methods, 2001, 91-101, vol. 248.
[cited by applicant]
Pierce, “Lipid rafts and B-cell activation” Nat Rev Immunol., 2002, 96-105, vol. 2, No. 2.
[cited by applicant]
Prakken, et al “Heat shock protein 60 and adjuvant arthritis: a model fort cell regulation in human arthritis” Springer Seminars in Immunopathology, 2003, 47-63, vol. 25, No. 1.
[cited by applicant]
Pritchard, et al “B cell inhibitory receptors and autoimmunity” Immunology, 2003, 263-273, vol. 108, No. 3.
[cited by applicant]
Radaev, et al “The structure of a human type III Fcγ receptor in complex with Fe” J. Bio. Chem., 2001, 16468-16477, vol. 276, No. 19.
[cited by applicant]
Radaev, et al “Recognition of IgG by Feγ receptor” J. Biol. Chem., 2001, 16478-16483, vol. 276, No. 19.
[cited by applicant]
Raghavan, et al “Fc receptors and their interactions with immunoglobulins” Annu. Rev. Cell Dev. Biol., 1996, 181-220, vol. 12.
[cited by applicant]
Ramsland et al., “Structural Basis for FcγRIIa Recognition of Human IgG and Formation of Inflammatory Signaling Complexes”, J. Immunol., vol. 187, 2011, pp. 3208-3217.
[cited by applicant]
Rankin et al., “CD32B, The Human Inhibitory Fc-γ Receptor IIb, as a Target for Monoclonal Antibody Therapy of B-Cell Lymphoma”, Blood, vol. 108, 2006, pp. 2384-2391.
[cited by applicant]
Ravetch, et al.“IGG Fc Receptors” Annu. Rev. Immunol., 2001, 275-290, vol. 19.
[cited by applicant]
Ravetch, et al“Immune inhibitory receptors: Frontiers in cellular immunology” Science,2000, 84-89, vol. 290, No. 5489.
[cited by applicant]
Restriction Requirement, U.S. Appl. No. 12/156,183, filed Aug. 2, 2010 (8 pages).
[cited by applicant]
Restriction Requirement, U.S. Appl. No. 13/689,528, filed Jan. 21, 2015 (6 pages).
[cited by applicant]
Restriction Requirement, U.S. Appl. No. 13/294,103, filed May 11, 2012 (9 pages).
[cited by applicant]
Restriction Requirement, U.S. Appl. No. 13/594,619, filed Oct. 18, 2012 (7 pages).
[cited by applicant]
Restriction Requirement, U.S. Appl. No. 13/301,627, filed Apr. 30, 2012 (8 pages).
[cited by applicant]
Roque, et al “Antibodies and genetically engineered related molecules: Production andPurification” Biotechnol. Prag., 2004, 639-654, vol. 20.
[cited by applicant]
Rosenblum et al., “Treating Human Autoimmunity: Current Practice and Future Prospects”, Scu Trabsk Ned, vol. 14, No. 4, Issue 125, 2012, pp. 1-20.
[cited by applicant]
Samuelsson, et al “Anti-inflammatory activity of IVIG mediated through the inhibitory Fe receptor”Science, 2001, 484, vol. 291.
[cited by applicant]
Sarmay et al., “Integration of activatory and inhibitory signals in human B-cells,” Immunology Letters 54 (1996) 93-100.
[cited by applicant]
Scallon, et al, “Higher levels of sialylated Fe glycans in immunoglobulin G molecules can adverselyimpactfunctionality” Mol. Immunol., 2007, 1524-1534, vol. 44, No. 7.
[cited by applicant]
Shields, et al “High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR” J. Biol. Chem, 2001, 6591-6604, vol. 276, No. 9.
[cited by applicant]
Shields, et al “Lack of fucose on human IgG1 n-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity” J. Biol. Chem., 2002, 26733-26740, vol. 277, No. 30.
[cited by applicant]
Shinkawa, et al “The absence of fucose but not the presence of galactose or bisecting N-Acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cyto…
[cited by applicant]
Shopes, et al “A genetically engineered human IgG mutant with enhanced cytolyticactivity” J. Immunol., 1992, 2918-2922, vol. 148.
[cited by applicant]
Simmons, et al “Expression of full-length immunoglobulins in
[cited by applicant]
Smith, “Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface” Science, 1985, 1315-1317.
[cited by applicant]
Smith et al., “Mouse model recapitulating human Fcγ receptor structural and functional diversity”, PNAS, vol. 109, No. 16, 2012, pp. 6181-6186.
[cited by applicant]
Sonderman, et al“The 3.2-A crystal structure of the human IgG1 Fc fragment-FcyRIIIcomplex” Nature, 2000, 267-273, vol. 406.
[cited by applicant]
Sonderman, et al “Molecular basis for immune complex recognition: A comparison of Fc-Receptor structures” J. Mol. Biol., 2001, 737-749, vol. 309.
[cited by applicant]
Stefanescu, et al “Inhibitory Fc Gamma Receptors: From Gene to Disease” J. ClinicalImmunol., 2004, 315-326, vol. 24, No. 4.
[cited by applicant]
Stevenson, et al “Engineered antibody for treating lymphoma” Recent Res. In Cancer Research, 2002, 105-112, vol. 159.
[cited by applicant]
Su, et al “Expression profile of FcγRIIb on leukocytres and its dysregulation in systemic lupuserythematosus” J. Immunol., 2007, 3272-3280, vol. 178, No. 5.
[cited by applicant]
Tan, et al “‘Superhumanized’” Antibodies: Reduction of Immunogenic Potential by Complementarity-Determining Region Grafting with Human Germline Sequences: Application to an Anti-CD28 J.Immunol., 2002, 1119-1125, vol. 16…
[cited by applicant]
Tan, et al “CD40-CD40L interaction in Alzheimer's disease” Current Opinion in Pharmacology, 2002, 445-451, vol. 2.
[cited by applicant]
Thrush, et al., “Immunotoxins: An Update” Ann. Rev. Immunol, 1996, 49-71, vol. 14.
[cited by applicant]
Tchorbanov, et al. “Selective silencing of DNA-specific B lymphocytes delays lupusactivity in MRL/Ipr mice” European J. Immuno., 2007, 3587-3596, vol. 37, No. 12.
[cited by applicant]
Terminal Disclaimer, U.S. Appl. No. 13/594,619, filed Feb. 19, 2015 (2 pages).
[cited by applicant]
Trail, et al “Monoclonal antibody drug conjugates in the treatment of cancer” Current Opinion in Immunology, 1999, 584-588, vol. 11.
[cited by applicant]
Tridandapani, et al“Role of ship in FcGamma RIIS-mediated inhibition of RASactiviation in B cells” Mole. Immunol., 1998, 1135- 1146, vol. 35, No. 17.
[cited by applicant]
Tsurushita, et al “Humanization of Monoclonal Antibodies” Molecular B Cells, 2004,533-545.
[cited by applicant]
Umana, et al “Engineered glycoforms of an antineuro-blastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity” Nature, 1999, 176-180, vol. 17.
[cited by applicant]
Vaz.Awa et al., Immunotherapy Using Unconjugated CD19 Monoclonal Antibodies InAnimal Models For B Lymphocyte Malignancies And Autoimmune Disease, PNAS, Oct. 10, 2005.
[cited by applicant]
Van Kooten et al., “CD40-CD40 ligand”, Journal of Leukocyte Biology, vol. 67, Jan. 2000, pp. 2-17.
[cited by applicant]
Van Loghem, et al “Allotypic Makers” Monogr. Allergy, 1986, 40-51, vol. 19.
[cited by applicant]
Verhoeyen, et al “Reshaping Human Antibodies: Grafting an Antilysozyme Activity” Science, 1988, 1534-1536, vol. 239, No. 4847.
[cited by applicant]
Veri, et al., “Monoclonal antibodies capable of discriminating the human inhibitory Fc gamma-receptor IIB (CD32B) from the activiatin Fc gamma-receptor IIA (CD32A): biochemical, biological, and functional characterizati…
[cited by applicant]
Vonderheide et al., “Clinical Activity and Immune Modulation in Cancer Patients Treated with CP-870,893, a Novel CD40 Agonist Monoclonal Antibody”, J. Clin. Oncol., vol. 25, No. 7, 2007, pp. 876-883.
[cited by applicant]
Weng, et al “Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma” J. Clin Oneal., 2003, 3940-3947, vol. 21.
[cited by applicant]
Wernersson, et al., “IGG-Mediated Enhancement of Antibody Responses is Low in FeReceptor Gamma Chain-Deficient Mice and Increased in FcγRII-Deficient Mice” J. Immunol., 1999, 618-622, vol. 163, No. 2.
[cited by applicant]
White et al., “Interaction with FcγRIIB is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody”, Journal of Immunology, vol. 187, 2011, pp. 1-10.
[cited by applicant]
Wilman, “Prodrugs in cancer chemotherapy” Biochemical Society Transactions, 1986, pp. 375-382.
[cited by applicant]
Wright, et al., “Effect of glycosylation on antibody function: Implications for genetic engineering” Trends in Biotechnology, 1997, 26-32, vol. 15, No. 1.
[cited by applicant]
Written Opinion of the International Searching Authority, PCT/US2008/06915, dated Dec. 1, 2009 (7 pages).
[cited by applicant]
Yamane-Ohnuki et al., Establishment Of FUT8 Knockout Chinese Hamster Ovary Cells: An Ideal Host Cell Line For Producing Completely Defucosylated Antibodies With Enhanced Antibody-Dependent Cellular Cytotoxicity, Wiley I…
[cited by applicant]
Yazawa et al., “Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease”, PNAS, vol. 102, No. 42, 2005, pp. 15178-15183.
[cited by applicant]
Yoshida, et al “Human Neonatal Fc Receptor Mediates Transport of IgG into Luminal Secretions for Delivery of Antigens to Mucosal Dendritic Cells” 2004, 769-783, vol. 20.
[cited by applicant]
Yuasa, et al “Deletion of FcGamma Receptor IIB Renders H-2B Mice Susceptible toCollagen-Induced Arthritis” J. Exp. Med., 1999, 187-194, vol. 189, No. 1.
[cited by applicant]
Zhang, et al “A new strategy for the synthesis of gylcoproteins” Science, 2004, 371-373, vol. 303.
[cited by applicant]
Zhukovsky, et al. “Xmab 5574: an FC engineered anti CD-19 monoclonal antibody within vitro and in vivo efficacy against Lymphoma and Leukemia” Internet Citation, www.Xencor.com, 2008.
[cited by applicant]